News & Updates
Filter by Specialty:
Brolucizumab noninferior to aflibercept in nAMD
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Do eyeglasses act as a shield against SARS-CoV-2 infection? Maybe—or maybe not
There is inconclusive evidence that wearing one’s eyeglasses can lower their chances of contracting COVID-19, according to a recent study.
Do eyeglasses act as a shield against SARS-CoV-2 infection? Maybe—or maybe not
01 Sep 2022
Dry eye disease: Too much water intake more harmful than beneficial
Drinking a lot of water does not seem to lower the risk of dry eye disease but may rather contribute to a modest risk increase, as reported in a recent cross-sectional study.
Dry eye disease: Too much water intake more harmful than beneficial
18 Aug 2022
Investigational nasal spray for dry eye disease scores high in phase II trial
The single-dose nicotinic acetylcholine receptor agonist OC-02, administered as an aqueous nasal spray, helps increase tear production and improve eye dryness in patients with dry eye disease (DED), according to data from the phase II PEARL trial.
